These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35611593)

  • 1. Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies.
    Ehlert K; Heinze B; Graham MA; Swanepoel D
    J Laryngol Otol; 2023 Jan; 137(1):61-67. PubMed ID: 35611593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
    Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
    Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR; Kraemer DF; Winter C; Neuwelt EA
    J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended High-Frequency Audiometry for Ototoxicity Monitoring: A Longitudinal Evaluation of Drug-Resistant Tuberculosis Treatment.
    Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
    Am J Audiol; 2023 Mar; 32(1):70-80. PubMed ID: 36490390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
    Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
    J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA; Dreschler WA; van der Hulst RJ
    Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin.
    De Lauretis A; De Capua B; Barbieri MT; Bellussi L; Passàli D
    Scand Audiol; 1999; 28(3):139-43. PubMed ID: 10489862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are There Cochlear Dead Regions Involved in Hearing Loss after Cisplatin Ototoxicity?
    Schultz C; Pecora Liberman PH; Schmidt Goffi-Gomez MV
    Audiol Neurootol; 2019; 24(5):253-257. PubMed ID: 31661686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
    Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
    Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR; Ruggiero A; Lucidi D; De Corso E; Sergi B; Conti G; Paludetti G
    Audiol Neurootol; 2016; 21(4):203-211. PubMed ID: 27286730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of high-frequency audiometry in early detection of ototoxicity.
    Dreschler WA; vd Hulst RJ; Tange RA; Urbanus NA
    Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ; Dreschler WA; Urbanus NA
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
    Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
    Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy.
    Baguley DM; Prayuenyong P
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):245-250. PubMed ID: 31865419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in vestibular and cochlear function following platinum-based chemotherapy: A preliminary report.
    Ehlert K; Heinze B; Graham MA; Swanepoel W
    Ear Nose Throat J; 2022 Sep; ():1455613221115042. PubMed ID: 36052943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.